Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 25, 2024, Imunon, Inc. (IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) on its proposed plan for a Phase 3 trial of IMNN-001 for the treatment of advanced ovarian cancer.</li><li>This includes the overall trial design, the target patient population, the treatment schedule, and the primarly endpoint.</li><li>The finalized protocol is on track to be submitted in December 2024 and we anticipate the 500-patient Phase 3 trial initiating in the first quarter of 2025.</li></ul>

On November 25, 2024, Imunon, Inc. (IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) on its proposed plan for a Phase 3 trial of IMNN-001 for the treatment of advanced ovarian cancer.This includes the overall trial design, the target patient population, the treatment schedule, and the primarly endpoint.The finalized protocol is on track to be submitted in December 2024 and we anticipate the 500-patient Phase 3 trial initiating in the first quarter of 2025.

IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001 